Trial Profile

Phase 3 Study of Ibrutinib in Combination With Venetoclax in Subjects With Mantle Cell Lymphoma

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 29 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibrutinib (Primary) ; Venetoclax (Primary)
Indications Mantle-cell lymphoma
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms SYMPATICO
Sponsors Pharmacyclics

Most Recent Events

27 May 2025 According to AbbVie media release, data from this trial will be presented at American Society of Clinical Oncology (ASCO) Annual Meeting.
01 Jul 2024 Status changed from active, no longer recruiting to completed.
04 Jun 2024 Results reporting efficacy and safety of Ibr+Ven in pts with TP53 mutations across cohorts, presented at the 60th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com